Want to see ARTV full AI Analyst Report?
Artiva Biotherapeutics, Inc. (ARTV) Stock Statistics & Valuation Metrics
Total Valuation
Artiva Biotherapeutics, Inc. has a market cap or net worth of $204.85M. The enterprise value is $42.76M.
- Market Cap
- $204.85M
- Enterprise Value
- $42.76M
Share Statistics
Artiva Biotherapeutics, Inc. has 48,890,120 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 48,890,120
- Owned by Insiders
- 56.13%
- Owned by Institutions
- 9.73%
Financial Efficiency
Artiva Biotherapeutics, Inc.’s return on equity (ROE) is -0.76 and return on invested capital (ROIC) is -74.94%.
- Return on Equity (ROE)
- -0.76
- Return on Assets (ROA)
- -0.64
- Return on Invested Capital (ROIC)
- -74.94%
- Return on Capital Employed (ROCE)
- -0.77
- Revenue Per Employee
- 0
- Profits Per Employee
- -729.26K
- Employee Count
- 115
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Artiva Biotherapeutics, Inc. is -1.27. Artiva Biotherapeutics, Inc.’s PEG ratio is -0.38.
- PE Ratio
- -1.27
- PS Ratio
- 0.00
- PB Ratio
- 0.48
- Price to FCF
- -2.09
- Price to Operating Cash Flow
- -1.72
- PEG Ratio
- -0.38
Income Statement
In the last 12 months, Artiva Biotherapeutics, Inc. had revenue of 0 and earned -83.86M in profits. Earnings per share was -3.43.
- Revenue
- 0
- Gross Profit
- -2.60M
- Operating Income
- -90.61M
- Pretax Income
- -83.86M
- Net Income
- -83.86M
- EBITDA
- -81.27M
- Earnings Per Share (EPS)
- -3.43
Cash Flow
In the last 12 months, operating cash flow was -96.18M and capital expenditures -1.92M, giving a free cash flow of -98.10M billion.
- Operating Cash Flow
- -96.18M
- Free Cash Flow
- -98.10M
- Free Cash Flow per Share
- -2.49
Dividends & Yields
Artiva Biotherapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -47.89%
- Earnings Yield
- -55.00%
Stock Price Statistics
- Beta
- 2.80
- 52-Week Price Change
- 6.35%
- 50-Day Moving Average
- 8.12
- 200-Day Moving Average
- 8.09
- Relative Strength Index (RSI)
- 20.66
- Average Volume (3m)
- 628.51K
Important Dates
Artiva Biotherapeutics, Inc. upcoming earnings date is Nov 18, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- Nov 18, 2026
- Ex-Dividend Date
- ―
Financial Position
Artiva Biotherapeutics, Inc. as a current ratio of 8.61, with Debt / Equity ratio of 9.95%
- Current Ratio
- 8.61
- Quick Ratio
- 8.61
- Debt to Market Cap
- 0.10
- Net Debt to EBITDA
- 0.19
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Artiva Biotherapeutics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Artiva Biotherapeutics, Inc. EV to EBITDA ratio is 0.99, with an EV/FCF ratio of 0.88.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.99
- EV to Free Cash Flow
- 0.88
- EV to Operating Cash Flow
- 0.90
Balance Sheet
Artiva Biotherapeutics, Inc. has $349.39M in cash and marketable securities with $9.85M in debt, giving a net cash position of $339.55M billion.
- Cash & Marketable Securities
- $349.39M
- Total Debt
- $9.85M
- Net Cash
- $339.55M
- Net Cash Per Share
- $6.95
- Tangible Book Value Per Share
- $8.82
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Artiva Biotherapeutics, Inc. is $11.00, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $11.00
- Price Target Upside
- 162.53% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 5
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -7.24%
Scores
- Smart Score
- 1
- AI Score
- 41